Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Consensus Rating of "Hold" by Brokerages

Key Points

• Zimmer Biomet Holdings, Inc. has received a consensus rating of "Hold" from eighteen research firms, with ratings varying from two sell ratings to nine buy ratings.
• The company recently reported $2.07 earnings per share, exceeding analysts' estimates and showing a 7.0% revenue increase year-over-year.
• Zimmer Biomet announced a quarterly dividend of $0.24 per share, to be paid on October 31st, representing an annual yield of 0.9%.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) has been assigned a consensus rating of "Hold" from the eighteen research firms that are currently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $111.00.

A number of research analysts have commented on ZBH shares. Raymond James Financial increased their price objective on Zimmer Biomet from $104.00 to $113.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. Evercore ISI cut their price target on Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 8th. Roth Capital reiterated a "buy" rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. Royal Bank Of Canada boosted their price objective on Zimmer Biomet from $112.00 to $115.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Finally, UBS Group raised their target price on shares of Zimmer Biomet from $91.00 to $96.00 and gave the company a "sell" rating in a research note on Friday, August 8th.

Zimmer Biomet Stock Up 1.9%

Shares of NYSE:ZBH opened at $104.22 on Friday. Zimmer Biomet has a 12 month low of $89.22 and a 12 month high of $114.72. The company's 50-day moving average price is $99.27 and its two-hundred day moving average price is $99.62. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. The firm has a market cap of $20.65 billion, a P/E ratio of 25.36, a P/E/G ratio of 2.35 and a beta of 0.68.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts' consensus estimates of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The company had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. During the same period in the previous year, the firm posted $2.01 earnings per share. The company's revenue was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, research analysts forecast that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. Zimmer Biomet's dividend payout ratio (DPR) is presently 23.36%.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the company's stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the sale, the senior vice president owned 6,833 shares in the company, valued at approximately $711,656.95. The trade was a 18.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.39% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ZBH. Brighton Jones LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at $204,000. Focus Partners Wealth lifted its holdings in Zimmer Biomet by 16.2% during the fourth quarter. Focus Partners Wealth now owns 16,528 shares of the medical equipment provider's stock worth $1,760,000 after acquiring an additional 2,303 shares in the last quarter. OMERS ADMINISTRATION Corp grew its stake in Zimmer Biomet by 19.9% in the fourth quarter. OMERS ADMINISTRATION Corp now owns 8,684 shares of the medical equipment provider's stock valued at $917,000 after acquiring an additional 1,443 shares during the period. Occudo Quantitative Strategies LP acquired a new position in Zimmer Biomet in the fourth quarter valued at about $648,000. Finally, Nuveen Asset Management LLC increased its holdings in shares of Zimmer Biomet by 191.8% in the fourth quarter. Nuveen Asset Management LLC now owns 1,389,405 shares of the medical equipment provider's stock worth $146,763,000 after acquiring an additional 913,310 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.